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Abstract - Nitric oxide inhibits adhesion of thrombocytes, proliferation and migration of smooth muscle cells and restricts 
oxidation of atherogenic low-density lipoproteins. Therefore, decreased production or activity of NO may play a role in the 
initiation, progression or complications of atherosclerosis. The aim of this study was to estimate the effect of Glu298Asp 
eNOS gene polymorphism on the individual risk for development of complicated carotid atherosclerotic plaque in pa-
tients from Serbia with advanced carotid atherosclerosis (CA) who had undergone endarterectomy. The study population 
included 233 patients. eNOS G894T gene polymorphism was identified by PCR and RFLP methods. Multivariate logistic 
regression analysis showed that Asp298Asp is an independent risk factor for the presence of complicated plaques in CA 
patients. Patients who were homozygous for the Asp298 allele had an adjusted OR of 4.36 for the development of compli-
cated plaques compared to those that carry the Glu298 allele. Further validation and replication studies are needed.
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INTRODUCTION
Nitric oxide (NO) is synthesized by the constitu-
tive expressed endothelial NOS (eNOS) encoded 
by the NOS3 gene, in endothelial cells, platelets and 
red blood cells ((Radomski et al., 1990; Kleinbon-
gard et al., 2006), as well in certain populations of 
nerve cells in the brain (Dinerman et al., 1994). NO 
is a major vasodilative substance released by the en-
dothelium. Nitric oxide has anti-inflammatory prop-
erties by inhibiting the synthesis and expression of 
cytokines and cell adhesion molecules that attract 
inflammatory cells to the endothelial surface and fa-
cilitate their entrance into the vessel wall (Bath et al., 
1991; De Caterina et al., 1995). It inhibits adhesion 
of thrombocytes as well (Randomski et al., 1987), 
proliferation and migration of smooth muscle cells 
(Garg and Hassid, 1989; Sarkar et al., 1996), and it 
restricts the oxidation of atherogenic low-density 
lipoproteins (LDL) (Hogg et al., 1993). Because of 
these properties, decreased production or activity of 
NO, manifested as impaired vasodilatation, may play 
a role in the initiation, progression or complications 
of atherosclerosis. 
Glu298Asp polymorphism in NOS3 exon 7 was 
first discovered by a group of French researchers. 
The G to T nonsynonymous polymorphism at posi-
tion 894 of the eNOS gene results in an amino acid 
change from Glu to Asp at codon 298 (Nadaud et al., 
1994).
There are several studies showing an associa-
tion of these polymorphisms with coronary heart 
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disease (Casas et al., 2006; Cooke et al., 2007). The 
few studies conducted on different populations 
reported conflicting results for associations of As-
p298Glu polymorphism with intima-media thick-
ness (IMT) (Lembo et al., 2001; Schmoelzer et al., 
2003) and the presence of carotid atherosclerotic 
plaques (Wollf et al., 2005; Djuric et al., 2009). 
However, data concerning the association of Glu-
298Asp eNOS gene polymorphism and a possible 
effect on the development of complicated carotid 
plaques has not been evaluated so far. The aim of 
our study was to estimate the effect of Glu298Asp 
eNOS gene polymorphism on the individual risk 
for development of complicated carotid atheroscle-
rotic plaque in patients from Serbia with advanced 
carotid atherosclerosis (CA) who had undergone 
endarterectomy. 
MATERIALS AND METHODS
Subjects
The 233 patients enrolled in the study were re-
cruited from the Clinic for Vascular and Endovas-
cular Surgery, Clinical Center of Serbia, Belgrade, 
Serbia (2008-2009) and were comprised of subjects 
consecutively admitted for carotid endarterectomy 
with evidence of carotid plaque presence in the in-
ternal (ICA) or common (CCA) carotid artery. All 
of them were Caucasians of European descent from 
Serbia. Exclusion criteria for all patients were a his-
tory of previous carotid endarterectomy (possible 
restenosis), carotid kinking, carotid aneurism, tu-
mors, chronic inflammatory diseases, autoimmune 
disease or renal failure. For all individuals enrolled 
in the study, a complete medical history was taken, 
including smoking and drinking habits, the pres-
ence of diabetes, coronary artery disease, periph-
eral arterial occlusive disease and drug treatment. 
Subjects already diagnosed with diabetes mellitus 
(fasting glucose level of ≥7.0 mmol/l) or taking 
insulin or oral hypoglycemic drugs were charac-
terized as having diabetes mellitus; those with pre-
vious myocardial infarction or with stable angina 
pectoris evaluated by selective coronarography that 
confirmed or revealed coronary artery disease were 
characterized as having coronary heart disease. Pe-
ripheral artery disease was diagnosed as an ankle-
brachial index (ABI) lower than 0.90. Hypertension 
was defined as a systolic blood pressure ≥140 mm 
Hg, diastolic blood pressure ≥90 mm Hg, or current 
treatment with an antihypertensive drug.
All biochemical analyses were performed at the 
hospital laboratory by standard procedures.
The study was approved by the Ethics Commit-
tees of the participating medical center and partici-
pants gave their written informed consent to partici-
pate in the study.
Ultrasound assessment of the carotid arteries
Ultrasound assessment of the bilateral carotid arter-
ies was performed by high-resolution B-mode ultra-
sound Acuson Antares™ system (Siemens, Munich, 
Germany) and HDL 3500 linear transducer (5 to 12 
MHz.; Philips ATL, Bothell, WA). The degree of ca-
rotid stenosis was calculated using the European Ca-
rotid Surgery Trialists’ Collaborative Group method 
(ECST) (European Carotid Surgery Trial, 1991). The 
highest peak systolic (PSV) and end-diastolic (EDV) 
velocities as well as the ICA/CCA carotid artery ra-
tio, were recorded. All patients included in the study 
had stenosis >85% according to ECST.
Atherosclerotic plaques were defined as focal 
widening relative to adjacent segments as evidenced 
by protrusion into the lumen and/or localized rough-
ness with increased echogenicity. For ultrasound ca-
rotid measures, the intraclass correlation coefficient 
for inter-rater and intra-rater reliability was 0.916 
and 0.968, respectively. Carotid atherosclerosis was 
defined as the presence of atherosclerotic plaques in 
the internal or common carotid artery.
Duplex ultrasound analysis was used to classify 
different plaque types in terms of hypoechogenic 
(echolucent and dominantly echolucent) and hyper-
echogenic (echogenic and dominantly echogenic) 
according to the Gray-Weale criteria (Gray-Weale 
et al., 1988). Additionally, B mode was used to ana-
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lyze surface irregularity of the plaque (irregular 0.4-2 
mm). Plaque ulceration was defined as irregularity 
greater than 2 mm. Hypoechogenic plaques as well 
as plaques with ulcerations were defined as compli-
cated, while hyperechogenic plaques were defined as 
stable plaques. 
Genetic analysis
Genomic DNA was isolated from whole blood sam-
ples collected with EDTA by the standardized Blood-
Prep® DNA Chemistry isolation kit (Applied Biosys-
tems, Forester City, CA) on the ABI PRISM™ 6100 
Nucleic Acid PrepStation (Applied Biosystems, For-
ester City, CA). eNOS G894T gene polymorphism 
was identified by PCR and MboI (MBI Fermentas, 
Lithuania) restriction digestion, as previously de-
scribed (Hirata et al., 2002). The digestion products 
were loaded on an 8 % polyacrylamide gel for geno-
typing and run for 2 h at 12V/cm. Gels were stained 
with silver nitrate and visualized using a GDS8000 
gel documentation system (Ultra Violet Products 
Inc, Upland, USA).
Statistical analysis
The allelic frequencies and genotype distribution 
were estimated by the gene counting method. Dif-
ferences in allele frequencies and genotype distri-
bution between the cases and controls as well as 
deviation from Hardy-Weinberg equilibrium were 
estimated by chi-square (χ2). Means of normally 
distributed continuous variables were compared by 
unpaired t-test and means of skewed continuous 
variables with the nonparametric Mann-Whitney 
U Test. Statistical analysis was performed using 
Statistica Version 8, software package (StatSoft Inc, 
2007). As a measure of strength of association be-
tween eNOS genotypes and plaque types, multiple 
logistic regression analysis was used and expressed 
in terms of crude and adjusted OR and 95% confi-
dence interval (CI). The odds ratio was adjusted for 
glucose level and active antihypertensive therapy. 
The genotype effects were examined and represent-
ed according to a recessive model (Glu298Glu + 
Glu298Asp vs. Asp298Asp). In all tests, differences 
with two-tailed alpha-probability p<0.05, were con-
sidered significant.
RESULTS
The main characteristics of the patients according 
to plaque type (stable and complicated) are shown 
in Table 1. Patients with complicated plaques had a 
lower glucose serum level and were on active antihy-
pertensive therapy in higher percentage than patients 
with stable plaques. No other measured parameters 
were statistically different between the two investi-
gated groups of patients.
The genotype frequencies for eNOS Glu298Asp 
gene polymorphism did not deviate from the Hardy-
Weinberg equilibrium in any of the studied groups. 
Distribution of eNOS Glu298Asp genotype and al-
lele frequencies were significantly different between 
patients with stable and patients with complicated 
plaques (overall χ2 = 9.68, df=2, p<0.01) (Table 2). 
There was a significantly higher frequency of As-
p298Asp genotype in patients with complicated 
plaques compared to patients with stable plaques, 
according to the recessive model (16.67% vs. 5.37%, 
p<0.01 respectively) (Table 2). Multivariate logistic 
regression analysis showed that Asp298Asp is an 
independent risk factor for the presence of compli-
cated plaques in CA patients. Patients who were ho-
mozygous for the Asp298 allele had an adjusted OR 
of 4.36 for the development of complicated plaques 
compared to those that carried the Glu298 allele (the 
OR was adjusted for glucose level and active antihy-
pertensive therapy) (Table 2).
DISCUSSION
Glu298Asp polymorphism in the eNOS gene is still a 
questionable marker for the formation and progres-
sion of atherosclerosis in different populations. So 
far it has been tested in the population of Serbia as a 
marker for the development of carotid atherosclero-
sis (Djurić et al., 2009), but the aim of this study was 
to investigate the interindividual differences among 
patients with advanced atherosclerosis at risk for 
the development of complicated plaque. We found 
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Table 1. General characteristics of patients according to type of atherosclerotic plaque.
Variable Stable plaque n=149 Vulnerable plaque n=84 p-Value
Male/Female 81(54.36)/68(45.64) 50(58.82)/35(41.18) 0.51
Age, year 67.0±9.6 66.0±8.0 0.40
BMI (kg/m2) * 26.1±2.7 27.2±3.8 0.07
TC (mmol/L) * 5.81±1.20 5.81±1.78 0.95
TG (mmol/L) * 1.86±0.99 1.81±0.91 0.79
HDL (mmol/L) 1.16±0.34 1.16±0.36 1.00
LDL (mmol/L) 3.89±1.03 3.81±1.04 0.67
DDIM (mmol/L)* 214.8±199.2 235.4±307.3 0.73
Apo A1 (g/L) * 1.59±0.52 1.44±0.36 0.06
Apo B (g/L) * 1.16±0.30 2.72±12.58 0.88
CRP (mg/L) * 9.26±17.90 4.16±6.00 0.18
WBC (cells/µL )* 7.70±1.68 7.57±2.03 0.33
Glucose (mmol/L) * 7.10±2.72 6.26±2.65 <0.01
LDH (U/L) 331.84±75.63 316.00±73.20 0.14
Creatine (mmol/L)* 101.37±99.80 94.67±23.70 0.94
Fibrinogen (g/L)* 4.87±1.54 5.09±1.73 0.64
ASY n (%) 58 (39.29) 25 (29.63) 0.17
CVI n (%) 45 (30.20) 22 (25.88) 0.48
CAD n (%) 47 (31.25) 7 (8.33) 0.10
HLP n (%) 42 (28.19) 32 (38.10) 0.12
DMT II n (%) 43 (28.86) 22 (25.88) 0.62
Hypertension n (%) 125 (83.89) 70 (82.35) 0.76
Smokers n (%) 80 (53.69) 47 (55.29) 0.81
PAD n (%) 21 (14.19) 12 (14.12) 0.99
Actual therapy:
AAGR n (%) 104 (69.84) 42 (50.00) 0.18
AHT n (%) 86 (57.52) 67 (80.25) <0.01
ACT n (%) 5 (3.54) 3 (3.70) 0.95
Statins n (%) 26 (17.70) 16 (18.52) 0.88
Values are mean ± SD, for age, Body Mass Index (BMI), Total Cholesterol (TC), Triglycerides (TG), High Density Lipoproteins Choles-
terol (HDLC), Low Density Lipoproteins Cholesterol (LDLC), D-Dimer (DDIM), Apolipoprotein A1 (Apo A1), Apolipoprotein B (Apo 
B), C-Reactive Protein (CRP), White Blood Cells (WBC), glucose, Lactate Dehydrogenase (LDH), creatine and fibrinogen; χ2-test was 
used for categorical variables; Student’s t-test was used to compare age, HDLC, LDLC and LDH values; * BMI, TC, TG, DDIM, Apo A1, 
Apo B, CRP, WBC, glucose, creatine and fibrinogen values were compared using Mann-Whitney U-test; p values < 0.05 were considered 
statistically significant.
ASY - Asymptomatic patients, CVI - cerebrovascular insult, CAD - coronary artery disease, HLP - hyperlipidemia, DMT II - diabetes 
mellitus type 2, PAD - peripheral arterial disease, AAGR - antiaggregation therapy, AHT - antihypertensive therapy, ACT - anticoagulant 
therapy.
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that the Asp298Asp genotype was significantly and 
independently associated with the presence of com-
plicated plaque in Serbian CA patients. Reference 
data concerning the association of Glu298Asp eNOS 
gene polymorphism with the risk for development of 
complicated plaque as such has not been evaluated in 
any other population yet. Instead, it has been inves-
tigated as a marker of a cardiovascular event such as 
MI or stroke.
Studies on animal and human models show that 
the function of the endothelial nitric oxide is re-
duced in proatherogenic conditions, such as hyper-
cholesterolemia, diabetes mellitus and hypertension, 
which indicates that the reduction of available NO in 
the cardiovascular system precedes the progression 
of atherosclerotic lesions (Cooke and Dzau, 1997). 
NO, thus, inhibits the initiation and progression of 
atherosclerotic plaque and activation of inflammato-
ry factors that could contribute to plaque instability 
and rupture (Davignon et al., 2004). A paper by Te-
sauro et al. (2000) suggests that the eNOS wild-type 
Glu298 and the Asp298 variant are processed differ-
ently in native endothelial cells and vascular tissues. 
The Asp298 variant undergoes selective proteolysis, 
which produces smaller fragments that are probably 
nonfunctional or exert a dominant negative effect, 
so the steady state level of active eNOS may be re-
duced in carriers of this allele (Tesauro et al., 2000). 
Veldman et al. (2002) showed that the Asp298 allele 
is associated with reduced basal NO production in a 
healthy population of the Netherlands. Some stud-
ies reported that the Asp variant is associated with 
lower eNOS enzyme activity levels in human placen-
tas and umbilical vein (Wang et al., 2000; Joshi et al., 
2007). The Asp298 allele is also associated with re-
duced production of NO in pregnancy and in male 
smokers (Cooke et al., 2007). Moreover, in a recent 
study it was observed that the amount of eNOS en-
zyme associated with Cav-1 protein is significantly 
reduced in carriers of the Asp298 allele, either in ho-
mozygous or heterozygous state. In accordance with 
the fact that only Cav-1-associated eNOS can be ac-
tivated after reception of an activation signal to the 
cell, it is clear that the presence of an eNOS Asp298 
variant may affect the function of the enzyme (Joshi 
and Bauer, 2008).
This depletion of NO could be associated with 
thrombus formation in the arterial wall as well as 
with the higher levels of oxidative stress that are fea-
tures of complicated plaques formation and rupture. 
In line with this are the results from the study con-
ducted on healthy nonsmoker Caucasians aged 18 to 
45 years. The authors associated genotypes contain-
ing Asp298 allele with decreased NO production in 
platelets. After incubation of the platelet-rich blood 
with estradiol, which inhibits platelet aggregation 
through activation of eNOS, they obtained signifi-
cantly increased platelet aggregation and superox-
ide synthesis in platelets in individuals homozygous 
for the Asp298 allele (Tanus-Santos et al., 2002). It 
is already well known that superoxide contributes to 
the oxidative modification of LDL (Panasenko et al., 
1991), a critical event in development of an athero-
sclerotic lesion (Schwartz et al., 1991). The presence 
of oxidized LDL in atheromatous plaques correlates 
with progression of atherosclerotic carotid disease 
(Salonen et al., 1992) and promotes the transition 
from stable plaques to unstable plaques (Xu et al., 
1999).
The other negative feature of NO depletion is 
platelet aggregation. Occlusive or nonocclusive for-
mation of thrombus on atherosclerotic plaque is 
believed to be of prime importance in the progres-
sion of atherosclerosis, as well as the cause of acute 
coronary syndrome (Kubo-Inoue et al., 2002). It has 
been shown that platelets from patients with acute 
coronary syndromes produce significantly less NO 
compared to patients with stable coronary artery dis-
ease (Freedman et al., 1997). In addition, long-term 
inhibition of nitric oxide synthesis has been shown 
to increase arterial thrombogenecity in rat carotid 
artery (Kubo-Inoue et al., 2002). Having in mind that 
advanced atherosclerosis is a long-term inflamma-
tory disease, patients homozygous for 298Asp allele 
could be chronically exposed to much lower levels of 
NO compared with patients carrying genotypes with 
wild-type 298Glu allele.  
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Considering all the above facts, we can conclude 
that the Asp298Asp genotype could be a promising 
marker for interindividual differences in the risk for 
complicated plaque development in patients with ad-
vanced atherosclerosis from Serbia. Still, we must be 
aware that the number of patients included in this 
study was too limited to make a final conclusion. 
This result must be validated on a larger number of 
patients from Serbia as well as replicated in other 
populations.
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